MedPath

Salsalate

Generic Name
Salsalate
Drug Type
Small Molecule
Chemical Formula
C14H10O5
CAS Number
552-94-3
Unique Ingredient Identifier
V9MO595C9I
Background

Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo. Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body. The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.

Indication

For relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorders.

Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy

Phase 2
Completed
Conditions
Peripheral Neuropathy
Type 1 Diabetes
Interventions
First Posted Date
2011-11-28
Last Posted Date
2015-04-24
Lead Sponsor
University of Michigan
Target Recruit Count
8
Registration Number
NCT01480297
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Effects of Salsalate on Prandial-Induced Vascular Inflammation After Spinal Cord Injury (SCI)

Not Applicable
Completed
Conditions
Spinal Cord Injury
Interventions
Drug: Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.
First Posted Date
2010-09-15
Last Posted Date
2015-06-10
Lead Sponsor
University of Miami
Target Recruit Count
18
Registration Number
NCT01201759
Locations
🇺🇸

The Miami Project to Cure Paralysis, Miami, Florida, United States

Salsalate for Insulin Resistance in Schizophrenia

Not Applicable
Completed
Conditions
Insulin Resistance
Schizophrenia
Interventions
First Posted Date
2010-08-17
Last Posted Date
2022-03-11
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
13
Registration Number
NCT01182727
Locations
🇺🇸

Baltimore VA Medical Center, Baltimore, Maryland, United States

🇺🇸

Maryland Psychiatric Research Center, Baltimore, Maryland, United States

Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults

Phase 2
Completed
Conditions
Inflammation
Endothelial Dysfunction
Insulin Resistance
HIV
Interventions
First Posted Date
2010-01-12
Last Posted Date
2015-01-07
Lead Sponsor
University Hospitals Cleveland Medical Center
Target Recruit Count
40
Registration Number
NCT01046682
Locations
🇺🇸

University Hospitals Case Medical Center, Cleveland, Ohio, United States

Vascular Function, Endothelin, and Inflammation in Pre-diabetic Obesity Versus Lean Healthy Controls

Phase 1
Terminated
Conditions
Obesity
Pre-diabetes
Interventions
First Posted Date
2009-02-05
Last Posted Date
2019-08-01
Lead Sponsor
Indiana University
Target Recruit Count
16
Registration Number
NCT00837590
Locations
🇺🇸

Indiana Clinical Research Center, Indianapolis, Indiana, United States

Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II

Phase 2
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
First Posted Date
2008-12-01
Last Posted Date
2017-12-11
Lead Sponsor
Joslin Diabetes Center
Target Recruit Count
638
Registration Number
NCT00799643
Locations
🇺🇸

Emory University School of Medicine, Atlanta, Georgia, United States

🇺🇸

Kaiser Permanente, Tucker, Georgia, United States

🇺🇸

University of Texas Southwestern, Dallas, Texas, United States

and more 18 locations

Inflammation and Vascular Function in Atherosclerosis

Phase 2
Completed
Conditions
Atherosclerosis
Interventions
Drug: placebo
First Posted Date
2008-09-25
Last Posted Date
2017-05-16
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
58
Registration Number
NCT00760019
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Targeting Inflammation Using Salsalate in CardioVascular Disease

Phase 2
Completed
Conditions
Overweight
Coronary Artery Disease
Interventions
Drug: Placebo
First Posted Date
2008-02-28
Last Posted Date
2019-05-07
Lead Sponsor
Joslin Diabetes Center
Target Recruit Count
340
Registration Number
NCT00624923
Locations
🇺🇸

Joslin Diabetes Center, Boston, Massachusetts, United States

🇺🇸

Heart Center of Metrowest, Framingham, Massachusetts, United States

🇺🇸

Seacoast Cardiology, York, Maine, United States

and more 2 locations

Effect of Salsalate on Bed Rest-Induced Vascular Dysfunction

Phase 1
Completed
Conditions
Insulin Resistance
Interventions
Drug: Placebo
First Posted Date
2007-11-06
Last Posted Date
2017-03-10
Lead Sponsor
Boston University
Target Recruit Count
60
Registration Number
NCT00553995
Locations
🇺🇸

Boston University School of Medicine, Boston, Massachusetts, United States

Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)

Phase 2
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: Placebo
First Posted Date
2006-10-26
Last Posted Date
2019-04-08
Lead Sponsor
Joslin Diabetes Center
Target Recruit Count
277
Registration Number
NCT00392678
Locations
🇺🇸

Endocrine Clinical Research, Winter Park, Florida, United States

🇺🇸

Kaiser Permanente, Atlanta, Georgia, United States

🇺🇸

Emory School of Medicine, Atlanta, Georgia, United States

and more 13 locations
© Copyright 2025. All Rights Reserved by MedPath